Eli Lilly and Co. CEO David Ricks ... $250 million over the next eight years to foster pharmaceutical innovation. The initiative, called Lilly-Purdue 360, is focused on efforts including ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

INDIANAPOLIS and WEST LAFAYETTE, May 9, 2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their long-standing alliance ... at every ...

Sidekick is also working with a number of other pharma companies on companion ... and other chronic conditions. The new Lilly alliance is one of three that Sidekick expects to announce in the ...

In its second R&D alliance this week, Eli Lilly has formed a partnership with ... Earlier this week, the pharma group announced a $1 billion alliance with Swiss start-up Haya Therapeutics to ...

INDIANAPOLIS and WEST LAFAYETTE, Ind. - Eli Lilly and Company (NYSE: LLY), a pharmaceutical giant with annual revenue exceeding $49 billion and an impressive 81.7% gross profit margin, and Purdue ...

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

Eli Lilly and Purdue University ... investment of up to $250m over the next eight years by Lilly, to expedite innovation across the pharma pipeline. The Lilly-Purdue 360 Initiative focuses ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

Eli Lilly and Co. and Purdue University announced today a significant expansion of their long-standing alliance ... innovation at every stage of the pharmaceutical pipeline.